Download PDF
Aktuelle Neurologie 2011; 38: S11-S16
DOI: 10.1055/s-0030-1265967
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Apomorphininjektionstherapie bei Morbus Parkinson

Apomorphine Injection Therapy for Parkinson's DiseaseP.  Odin1 , 2 , A.  Bilsing3 , J.  Durner4 , H.  Honig1
  • 1Abt. Neurologie, Klinikum-Bremerhaven, Bremerhaven, Deutschland
  • 2Abt. Neurologie, Universitätskrankenhaus, Lund, Schweden
  • 3Abt. Neurologie, Ambulantes Reha-Zentrum Hunsrück, Kastellaun
  • 4Abt. Neurologie, m&i Fachklinik Ichenhausen
Further Information

Publication History

Publication Date:
22 February 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Subkutane Apomorphininjektionen sind eine wertvolle und effektive Therapie für Parkinsonpatienten, die trotz optimierter oraler Therapie noch wiederholte „Off”-Phasen zeigen. Die durchschnittliche tägliche „Off”-Zeit kann halbiert werden und die noch bestehenden „Off”-Perioden sind milder ausgeprägt. Diese Effekte sind auch über längere Zeit stabil und es gibt keinen Anhalt für eine Toleranzentwicklung. Die Nebenwirkungen sind meistens gering ausgeprägt. Der beste Effekt wird erreicht, wenn Apomorphin bei relativ jungen, aktiven und kognitiv nicht eingeschränkten Patienten eingesetzt wird. Subkutane Apomorphininjektionen können oft das Weiterarbeiten und das Führen eines normalen Lebens ermöglichen. Apomorphin bietet eine zuverlässige Möglichkeit, schnell aus einer „Off”-Phase zu kommen. Dies führt zu mehr Unabhängigkeit und Selbstvertrauen bei den Betroffenen.

Abstract

Apomorphine as subcutaneous injections offers a valuable and effective treatment alternative for Parkinson patients with oral medication-resistant „off” phases. Its efficacy is stable during long-term therapy, with no signs of patient tolerance. Adverse events are usually mild. The best results are obtained with relatively young, active, and cognitively intact patients. Intermittent s. c. apomorphine therapy can improve the patients' possibilities to continue to work and to live a normal social life, by offering increased freedom and self-confidence through a reliable, quick rescue from the disabling medication-resistant „off” phases.

Schlüsselwörter

Apomorphin - Injektion - Subkutan - Parkinson - Dopaminagonist

Keywords

apomorphine - injection - subcutaneous - Parkinson - dopamine agonist

Literatur

  • 1 LeWitt P A. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.  Neurology. 2004;  62 (S 04) S8-11
    CrossrefPubMedGoogle Scholar
  • 2 Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow-up.  J Neurol Neurosurg Psychiatry. 1998;  65 709-716
    CrossrefPubMedGoogle Scholar
  • 3 Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease.  J Neurosci Nurs. 2001;  33 21-38
    CrossrefPubMedGoogle Scholar
  • 4 Poewe W, Kleedorfer B, Wagner M et al. Side-effects of subcutaneous apomorphine in Parkinson's disease.  Lancet. 1989;  i (8646) 1084-1085
    PubMedGoogle Scholar
  • 5 Pollak P, Champay A S, Gaio J M et al. Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie de Parkinson.  Rev Neurol (Paris). 1990;  146 116-122
    PubMedGoogle Scholar
  • 6 Kempster P A, Iansek R, Larmour I. Intermittent subcutaneous apomorphine injection treatment for Parkinson's disease.  Aust NZ J Med. 1991;  21 314-318
    CrossrefPubMedGoogle Scholar
  • 7 Hughes A J, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years.  Mov Disord. 1993;  8 165-170
    CrossrefPubMedGoogle Scholar
  • 8 Merello M, Leiguarda R. Tratamiento de las fluctuationes motoras de la enfermedad de parkinson con inyecciones subcutaneas de apomorfina.  Medicina (B Aires). 1995;  55 5-10
    PubMedGoogle Scholar
  • 9 Esteban-Munoz J, Marti M J, Marin C et al. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations.  Clin Neuropharmacol. 1997;  20 245-252
    CrossrefPubMedGoogle Scholar
  • 10 Östergaard L, Werdelin L, Odin P et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  58 681-687
    CrossrefPubMedGoogle Scholar
  • 11 Dewey R B, Hutton T, LeWitt A et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected Apomorphine for parkinsonian off-state events.  Arch Neurol. 2001;  58 1385-1392
    CrossrefPubMedGoogle Scholar
  • 12 Factor S A. Literature review: Intermitten subcutaneous apomorphine therapy in Parkinson's disease.  Neurology. 2004;  62 S12-S17
    PubMedGoogle Scholar
  • 13 Stacy M. Apomorphine: North american clinical experience.  Neurology. 2004;  62 S18-S21
    PubMedGoogle Scholar
  • 14 Pfeiffer R F, Gutmann L, Hull K L the APO302 study investigators et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.  Parkinsonism Relat Disord. 2007;  13 93-100
    CrossrefPubMedGoogle Scholar
  • 15 Stacy M, Silver D. Apomorphine for the acute treatment of „off” episodes in Parkinson's disease.  Parkinsonism Relat Disord. 2008;  14 85-92
    CrossrefPubMedGoogle Scholar
  • 16 Pahwa R, Koller W C, Trosch R M APO303 study investigators et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.  J Neurol Sci. 2007;  258 137-143
    CrossrefPubMedGoogle Scholar
  • 17 Trosch R M, Silver D, Bottini P B. Intermittent subcutaneous apomorphine therapy for „off” episodes in Parkinson's disease: a 6-month open-label study.  CNS Drugs. 2008;  22 519-527
    CrossrefPubMedGoogle Scholar
  • 18 Düby S E, Cotzias G C, Papavasiliou P S et al. Injected apomorphine and orally administered levodopa in parkinsonism.  Arch Neurol. 1972;  27 474-480
    CrossrefPubMedGoogle Scholar
  • 19 Victor J FS, Pollak P, Gervason C L et al. Levodopa-induced diphasic dyskinesia improved by subcutaneous apomorphine.  Mov Disord. 1992;  7 283-284
    CrossrefPubMedGoogle Scholar
  • 20 Lees A J. Dopamine agonists in Parkinson's disease: a look at apomorphine.  Fundam Clin Pharmacol. 1993;  7 121-128
    CrossrefPubMedGoogle Scholar
  • 21 Frankel J P, Lees A J, Kemster P A et al. Subcutaneous apomorphine in the treatment of Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 96-101
    CrossrefPubMedGoogle Scholar
  • 22 Factor S A, Brown D L, Molho E S. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease.  Mov Disord. 2000;  15 167-169
    CrossrefPubMedGoogle Scholar
  • 23 Tison F, Wiart L, Guatterie M et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.  Mov Disord. 1996;  11 729-732
    CrossrefPubMedGoogle Scholar
  • 24 Edwards L L, Quigley E MM, Harned R K et al. Defecatory function in Parkinson's disease: response to apomorphine.  Ann Neurol. 1993;  33 490-493
    CrossrefPubMedGoogle Scholar
  • 25 Christmas T J, Kempster P A, Chapple C R et al. Role of subcutaneous apomorphine in Parkinsonian voiding dysfunction.  Lancet. 1988;  2 1451-1453
    PubMedGoogle Scholar
  • 26 Tyne H L, Parsons J, Sinnott A et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.  J Neurol. 2004;  251 1370-1374
    CrossrefPubMedGoogle Scholar
  • 27 LeWitt P A, Ondo W G, Van Lunen B et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating „off” episodes in advanced Parkinson disease.  Clin Neuropharmacol.. 2009;  32 89-93
    CrossrefPubMedGoogle Scholar
  • 28 Chen J J, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.  Clin Ther. 2005;  27 1710-1724
    CrossrefPubMedGoogle Scholar
  • 29 Deleu D, Hanssens Y, Northway M G. Subcutaneous Apomorphine: An evidence-based review of its use in Parkinson's disease.  Drugs Aging. 2004;  21 687-709
    CrossrefPubMedGoogle Scholar
  • 30 Gunzler S A. Apomorphine in the treatment of Parkinson disease and other movement disorders.  Expert Opin Pharmacother. 2009;  10 1027-1038
    CrossrefPubMedGoogle Scholar
  • 31 Haq I U, Lewitt P A, Fernandez H H. Apomorphine therapy in Parkinson's disease: a review.  Expert Opin Pharmacother. 2007;  8 2799-2809
    CrossrefPubMedGoogle Scholar
  • 32 Kolls B J, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.  Clin Neuropharmacol. 2006;  29 292-301
    CrossrefPubMedGoogle Scholar
  • 33 Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease.  Expert Opin Pharmacother. 2007;  8 1941-1950
    CrossrefPubMedGoogle Scholar
  • 34 Obering C D, Chen J J, Swope D M. Update on apomorphine for the rapid treatment of hypomobility („off”) episodes in Parkinson's disease.  Pharmacother. 2006;  26 840-852
    CrossrefPubMedGoogle Scholar
  • 35 O'Sullivan J D, Lees A J. Use of apomorphine in Parkinson's disease.  Hosp Med. 1999;  60 816-820
    PubMedGoogle Scholar
  • 36 Poewe W, Wenning G K. Apomorphine: an underutilized therapy for Parkinson's disease.  Mov Disord. 2000;  15 789-794
    CrossrefPubMedGoogle Scholar
  • 37 Trenkwalder C, Boesch S, Ceballos-Baumann A et al. Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease: Consensus statement.  Nervenarzt. 2008;  79 475-479
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Per Odin

Abt. Neurologie, Klinikum-Bremerhaven

Postbrookstr. 103

27574 Bremerhaven

Email: per.odin@klinikum-bremerhaven.de

      >